

September Report 2021

The Fund returned -1.23% during September, outperforming our benchmark by 2.96%.

The outperformance in September gave the Fund a first quarter return of 8.10%, outperforming our benchmark by 4.61%.

The dominant thematic that we saw throughout September in the MedTech sector was related to a volume slowdown as procedures were affected by a rise in the delta-strain. We started to see hospitals curb elective procedures to save bed space for COVID patients, as some of our portfolio companies warned of slowdowns affecting their third quarter volumes, such as Boston Scientific and Silk Road Medical. We expect more management teams to make similar announcements in the lead up to 3Q reporting season at the end of this month. We have also had first-hand evidence of this filtering through from our Medical Advisory Panel, and as a result have been tilting portfolio positioning to the companies more focussed on outpatient, or non-hospital based, procedures.

One of the more pleasing aspects of our performance in September came in the form of a bid for portfolio company Itamar Medical at a premium of 51%. We sold down our position throughout the rest of the month and have reallocated into other high conviction mid-cap growth names. While we always invest in companies for their fundamental growth potential, and never purely on M&A opportunity, we expect takeovers in the small cap part of our portfolio to continue to positively affect our returns.


The best performing large cap contribution came from Terumo Corp, as it continues to perform strongly as the dominant MedTech player in the APAC region. One indicator of its recent strong performance came during an online briefing about their Alliance Division, in which management outlined a global expansion for this business. Target growth for the Alliance Division is now sales CAGR of 15–20%. While Alliance is still an emerging part of the overall business, we believe it will accelerate Terumo’s growth nicely over the long term.

During the month we focussed much of our research on portfolio positioning in the electrophysiology space, highlighted by discussions with two leading EPs across different continents. This deep dive reinforced two of our key views. First was regarding the rapid growth of the left atrial appendage closure market, a duopoly dominated by Boston Scientific and Abbott. And second, was the first mover advantage provided to Boston and Medtronic through their Pulsed Field Ablation devices. We remain very positive on the growth in EP over our investment horizon.

Acutus Medical was a detractor on Fund performance in September, driven by negative sentiment around their August capital raising. However, we continue to believe in the ability of Acutus’ non-contact cardiac mapping system to take market share from incumbents over the next 2-3 years.

The fund is unhedged. The AUD depreciated 1.16% against the USD over September. In line with this, the Fund’s US-based and other foreign company positions, increased in AUD

PERFORMANCE VS BENCHMARK




	1 Month %	3 Month %	Since Inception %
Cordis	-1.23	8.10	8.10
Benchmark	-4.19	3.50	3.50
Outperformance	2.96	4.61	4.61

*inception was 1 July 2021

*numbers may not add due to rounding

GEOGRAPHICAL REVENUE EXPOSURE

North America	63.4%
Europe, Middle East & Africa	15.1%
APAC	16.0%
Rest of World	5.5%



PORTOLIO TOP 5 HOLDINGS (alphabetically)


Boston Scientific
DexCom Inc
Edwards Lifesciences Corp
Medtronic PLC
Terumo Corp

Past performance is not indicative of future performance.

The unit price performance calculation methodology follows the FSC Standard No.6: Investment Option Performance - Calculation of Returns (July 2018). Total returns are calculated based on changes in net asset values, at the exit price after the deduction of fees and expenses. Due to individual circumstances, your net returns may differ from the net returns quoted above.

ABOUT THE FUND

Cordis Global Medical Technology Fund is an Australian Unit Trust actively investing in a portfolio of global listed companies which make medical devices that provide treatments for critical chronic disease. The Cordis investment team is advised by our medical advisory panel of leading clinical physicians and medical device specialists, which we believe provides inimitable insight from frontline medical practice and principles. It is this resource that differentiates our research process from our competitors and provides us with a sustainable competitive advantage.



THE FUND

Website: www.cordisam.com
Fund Manager: Cordis Asset Management Pty Ltd
Responsible Entity: Equity Trustees Limited
Admin & Custodian: Mainstream Fund Services Pty Ltd
Sub-Custodian: J.P. Morgan Chase Bank
Fund Auditors: Ernst & Young
Minimum Investment: A\$50,000
Liquidity: Daily

To invest: Ask your advisor or see us at
<https://cordisam.com>

Disclaimers

This report was prepared by Cordis Asset Management Pty Ltd ABN 68 637 078 490 a corporate authorised representative (CAR No 001282680) of Lanterne Fund Services Pty Ltd ACN 098 472 587, AFSL 238198 ("Cordis"), the investment manager for the Cordis Medical Technology Fund ("Fund"). Equity Trustees Limited ("Equity Trustees") ABN 46 004 031 298 AFSL No. 240975, is a subsidiary of EQT Holdings Limited ABN 22 607 797 615, a publicly listed company on the Australian Securities Exchange (ASX:EQT), and is the Responsible Entity of the Fund. This document has been prepared for the purpose of providing general information only, without taking account of any individual person's investment objectives, financial circumstances or needs. Whilst every care has been taken in the production of this document, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. The information contained in this document is not intended to be relied upon as a forecast and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy, nor is it investment advice. Any forwarding-looking statements or forecasts are based on reasonable assumptions, but cannot be relied upon as guarantees or representation as to what future performance will actually occur. Unless otherwise specified, the information contained in this document is current as at the date of issue and all amounts are in Australian Dollars (AUD). You should consider the Product Disclosure Statement ("PDS") in deciding whether to acquire, or continue to hold, the product. A PDS and application form is available at www.cordisam.com. Cordis and Equity Trustees do not guarantee the performance of the Fund or the repayment of the investor's capital. To the extent permitted by law, neither Equity Trustees, Cordis, nor any of their related parties including its employees, directors, consultants, advisers, officers or authorised representatives, are liable for any loss or damage (including consequential loss or damage) arising directly or indirectly as a result of reliance placed on the contents of this report. Past performance is not indicative of future performance.

ABOUT THE MANAGER

Cordis Asset Management was set up in Sydney, Australia by leading international physicians, medical-device experts, and investment professionals, to capitalise on the specialised sub-sector of global MedTech companies.

The manager was founded in the belief that this specialised sub-sector of global MedTech companies, which provide device-based treatments for critical chronic disease, will continue to outperform the broader healthcare index.

It is the critical and imperative nature of such treatments, underpinned by the expectations of the world's aging population to live a longer more active life, that will drive robust growth in the earnings of these companies for the next decade or more.

Our intense focus and specialisation in the sector allows us to understand the nuances of Healthcare, and ultimately generate sustainable returns over the long-term.

BENCHMARKS AND FEES

Benchmark: S&P Global 1200 Healthcare Index in AUD
Management Fee: 1.2% p.a (including GST/RITC) of the monthly Net Asset Value
Performance Fee: 15% (incl GST/RITC) of the increase in net asset value of the Fund above the Benchmark, calculated and accrued monthly, paid annually in arrears, subject to highwater mark

INVESTMENT PORTFOLIO

Number of Securities: 23
Maximum Cash Holding: 10%
Currency Exposure: Unhedged